Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

A Multidisciplinary Quality Improvement Project to Improve Appropriate Inherited Thrombophilia Testing at VA Connecticut

Jenny J Xiang, Talib Dosani, Ronald G. Hauser, Danielle Cosentino, Naseema Merchant, Michal G. Rose

Blood (2022) 140 (Supplement 1): 7864–7865.

https://doi.org/10.1182/blood-2022-168044

Published: 2022

Journal Articles

Use of Denosumab after Zoledronic Acid in Patients with Multiple Myeloma: Real-World Experience from 2015 to 2019 at Yale Cancer Center

Talib Dosani, Anna Poteraj, Terri L. Parker, Noffar Bar, Sabrina L. Browning, Elan Gorshein, Tara Anderson, Karl Insogna, Natalia Neparidze

Blood (2021) 138 (Supplement 1): 4756.

https://doi.org/10.1182/blood-2021-147466

Published: 2021

Journal Articles

Plerixafor Overcomes Lenalidomide-Associated Stem Cell Collection Failure and Affects Collected Myeloid and Erythroid Progenitors

Talib Dosani, MD, Stanton L. Gerson, MD, Suchitra Sundaram, MBBS, Gina Hoffman, Fahrettin Covut, MD, Katharine A. Downes, MD, Robert W. Maitta, MD PhD, Marcos De Lima, MD, Ehsan Malek, MD

Blood (2017) 130 (Supplement 1): 1922.

https://doi.org/10.1182/blood.V130.Suppl_1.1922.1922

Published: 2017

Journal Articles

Immunologic Status Evaluated By the Absolute Lymphocyte/Monocyte Ratio Provides a Powerful Prognostic Tool for Newly Diagnosed Multiple Myeloma

Ehsan Malek, MD, Talib Dosani, MD, Raisa Pinto, MD, Fahrettin Covut, MD, Hugo Akabane, MD, James J. Driscoll, MD PhD, Marcos De Lima, MD

Blood (2016) 128 (22): 1862.

https://doi.org/10.1182/blood.V128.22.1862.1862

Published: 2016

Journal Articles

Biomarker Proteasome Levels Predict Response to Combination Therapy with Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients

Neha Korde, MD, Talib Dosani, Olga Simakova, PhD, Sham Mailankody, MD, Rene Costello, Mark Roschewski, MD, Constance Yuan, MD PhD, Maryalice Stetler-Stevenson, MD PhD, William D Figg, PharmD, Ola Landgren, MD PhD, Irina Maric, MD

Blood (2014) 124 (21): 2080.

https://doi.org/10.1182/blood.V124.21.2080.2080

Published: 2014

NARROW

A Multidisciplinary Quality Improvement Project to Improve Appropriate Inherited Thrombophilia Testing at VA Connecticut

Use of Denosumab after Zoledronic Acid in Patients with Multiple Myeloma: Real-World Experience from 2015 to 2019 at Yale Cancer Center

Plerixafor Overcomes Lenalidomide-Associated Stem Cell Collection Failure and Affects Collected Myeloid and Erythroid Progenitors

Immunologic Status Evaluated By the Absolute Lymphocyte/Monocyte Ratio Provides a Powerful Prognostic Tool for Newly Diagnosed Multiple Myeloma

Biomarker Proteasome Levels Predict Response to Combination Therapy with Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients

Email alerts

ASH Publications

American Society of Hematology

A Multidisciplinary Quality Improvement Project to Improve Appropriate Inherited Thrombophilia Testing at VA Connecticut

Use of Denosumab after Zoledronic Acid in Patients with Multiple Myeloma: Real-World Experience from 2015 to 2019 at Yale Cancer Center

Plerixafor Overcomes Lenalidomide-Associated Stem Cell Collection Failure and Affects Collected Myeloid and Erythroid Progenitors

Immunologic Status Evaluated By the Absolute Lymphocyte/Monocyte Ratio Provides a Powerful Prognostic Tool for Newly Diagnosed Multiple Myeloma

Biomarker Proteasome Levels Predict Response to Combination Therapy with Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only